"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 3 | 4 |
| 2000 | 3 | 1 | 4 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 3 | 6 |
| 2003 | 0 | 3 | 3 |
| 2004 | 2 | 4 | 6 |
| 2005 | 2 | 2 | 4 |
| 2006 | 1 | 0 | 1 |
| 2007 | 8 | 4 | 12 |
| 2008 | 5 | 1 | 6 |
| 2009 | 3 | 3 | 6 |
| 2010 | 2 | 8 | 10 |
| 2011 | 7 | 1 | 8 |
| 2012 | 7 | 5 | 12 |
| 2013 | 8 | 8 | 16 |
| 2014 | 5 | 2 | 7 |
| 2015 | 8 | 4 | 12 |
| 2016 | 6 | 4 | 10 |
| 2017 | 12 | 6 | 18 |
| 2018 | 13 | 5 | 18 |
| 2019 | 5 | 3 | 8 |
| 2020 | 11 | 3 | 14 |
| 2021 | 11 | 2 | 13 |
| 2022 | 6 | 1 | 7 |
| 2023 | 9 | 1 | 10 |
| 2024 | 8 | 6 | 14 |
| 2025 | 12 | 2 | 14 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. AIDS. 2026 May 01; 40(5):600-610.
-
Incidence of Cancers Among Children Living With HIV in Malawi After Widespread Availability of Antiretroviral Therapy: A Population-Based Study. JCO Glob Oncol. 2026 Mar; 12(3):e2500448.
-
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial. J Antimicrob Chemother. 2026 Mar 04; 81(4).
-
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20?years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar; 162:108213.
-
Novel application of dried blood spot tenofovir diphosphate to predict viral suppression in postpartum women with HIV in Malawi. AIDS. 2026 May 01; 40(5):589-599.
-
HIV-associated drug-resistant TB: expanded treatment options and emerging threats. Curr Opin HIV AIDS. 2026 Mar 01; 21(2):172-179.
-
Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIV. J Control Release. 2026 Feb 10; 390:114559.
-
PrEParing for Change: Using Quality Improvement to Provide HIV PrEP to Unhoused Youth and Young Adults. J Adolesc Health. 2026 Feb; 78(2):356-359.
-
Growing Up with HIV: A Comprehensive Review of Treatment and Care in Low- and Middle-Income Countries. Curr HIV/AIDS Rep. 2025 Nov 07; 22(1):52.
-
Retention in HIV Care Still Matters: A Longitudinal Multisite Analysis. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):123-130.